EUCODIS Bioscience - Tailored Biocatalysis

EUCODIS delivers high-performance enzyme solutions for highly specific applications in biopharma, fine chemicals, cosmetics industry and others.

With a portfolio of over 50 enzymes including innovative lipases, beta-lactamases, peroxidases and other enzymes EUCODIS Bioscience has a proven track record of providing customized enzyme solutions.

EUCODIS Bioscience provides customized services in recombinant protein and enzyme production by covering the whole spectrum of bioprocess development up to industrial-scale manufacture of your target proteins under ISO9001.

ProBioGen And Eucodis Sign Agreement to Commercialize C-LiNK, A Novel Antibody Drug Conjugation Technology

on .

Novel Enzymatic, 1-Step Site-Specific Protein Conjugation Technology for ADC Production

Berlin, Germany, and Vienna, Austria, April 19th: ProBioGen, a leading specialist for contract development and manufacturing of complex glycoproteins and Eucodis Bioscience, an expert in enzyme engineering, today jointly announced the signature of an exclusive license agreement on C-LiNK (CTAT), an innovative, site-specific ADC conjugation technology. Under the agreement ProBioGen gains exclusive rights to commercialize Eucodis’ enzymatic C-terminal linking technology, and to offer it, together with its antibody development services, royalty-free to ADC-developing parties.

Antibody Drug Conjugate Using CTAT Linker Technology Shows Superior Efficacy in Xenograft Trial

on .

CTATTM is an innovative enzymatic linker technology for conjugating different payloads with antibodies, without affecting their specificity, binding properties or stability. In the presented xenograft trial, the tested CTAT-ADC showed superior efficacy versus a commercially available ADC.